tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.

Launched by TONGJI UNIVERSITY · Jul 10, 2025

Keywords

ClinConnect Summary

1. Research purpose (1) This study aims to explore the synergistic therapeutic effect of tACS on negative symptoms and cognitive function in long-term hospitalized schizophrenia patients; (2) Using emotion-induced EEG activity in a virtual reality context as a biomarker, analyze its correlation with the clinical efficacy of tACS.
2. Expected results (1) It is confirmed that tACS can improve negative symptoms and cognitive function in long-term hospitalized schizophrenia patients; (2) Biomarkers can be used to predict the efficacy of tACS in improving negative symptoms and cognitive function...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Inclusion criteria for long-term hospitalized schizophrenia patients:
• • 1. Diagnosed with DSM-5 schizophrenia and hospitalized for more than half a year
• • 2. Aged between 18 and 65 years old
• • 3. Willing to participate in the study and sign the informed consent
• • 4. Stable condition, PANSS total score changed less than 15% at least 2 months before the study.
• • 5. Education level above primary school
• • 6. Normal vision or normal after correction
• Inclusion criteria for normal control group:
• • 1. No diagnosed mental illness
• • 2. Aged between 18 and 65 years old
• • 3. Willing to participate in the study and sign the informed consent
• • 4. Education level above primary school
• • 5. Normal vision or normal after correction
• • 6. Residents living in Pudong community
• Exclusion Criteria:
• Exclusion criteria for long-term hospitalization of schizophrenia patients:
• • 1. Combined diagnosis of other mental illnesses in DSM-5
• • 2. History of severe neurological diseases, epilepsy, craniocerebral trauma, etc.
• • 3. Severe organic diseases of the heart, liver, kidney and other organs that are unstable
• • 4. Infectious skin diseases
• • 5. Use of other drugs that affect the results during the study, such as benzodiazepines, non-benzodiazepine sedatives, and psychostimulants
• • 6. Pregnant or lactating women
• • 7. Patients with claustrophobia
• • 8. Patients with alcohol, drugs Abuse history
• • 9. Patients who have received TACS treatment in the past and have no effect or intolerance
• Exclusion criteria for normal control group:
• • 1. Patients with a history of severe neurological diseases, epilepsy, craniocerebral trauma, etc.
• • 2. Patients with severe organic diseases that cause instability of organs such as heart, liver, and kidney
• • 3. Patients with infectious skin diseases
• • 4. During the study, drugs that affect the results were used in combination, such as benzodiazepines, non-benzodiazepine sedatives, and psychostimulants
• • 5. Pregnant or lactating women
• • 6. Patients with claustrophobia
• • 7. Patients with a history of alcohol and drug abuse -